InsiderTrades.com logo
Bible Shocker: Have You Seen Elon Musk’s Miracle?
From InvestorPlace   |   Ad
Breaking News: Elon Musk Invents New Type of A.I. (Shocking) Elon Musk is about to shock the world again with this new type of A.I.… Minting new millionaires in the process.
Click here for the full story…

MBRX Insider Trading

Insider Ownership Percentage: 6.70%
Insider Buying (Last 12 Months): $159,990.30
Insider Selling (Last 12 Months): $0.00

Moleculin Biotech Insider Trading History Chart

This chart shows the insider buying and selling history at Moleculin Biotech by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Moleculin Biotech Share Price & Price History

Current Price: $5.08
Price Change: ▲ Price Increase of +0.05 (0.99%)
As of 05/17/2024 01:00 AM ET

This chart shows the closing price history over time for MBRX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
From Paradigm Press   |   Ad
You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.
Click here to find out that this 8,788% cryptocurrency is.

Moleculin Biotech Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/26/2023Jonathan P FosterCFOBuy1,932$10.35$19,996.205,370View SEC Filing Icon  
12/26/2023Robert E GeorgeDirectorBuy966$10.35$9,998.10977View SEC Filing Icon  
12/26/2023Walter V KlempCEOBuy12,560$10.35$129,996.0045,392View SEC Filing Icon  
11/25/2022Walter V KlempCEOBuy3,000$19.20$57,600.0027,326View SEC Filing Icon  
11/21/2022Walter V KlempCEOBuy1,500$17.25$25,875.0024,326View SEC Filing Icon  
11/16/2022Walter V KlempCEOBuy5,680$14.55$82,644.0021,176View SEC Filing Icon  
See Full Table
Forget Bitcoin: This $8 Stock Is the Next Big Thing
From Behind the Markets   |   Ad
4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.
Get the name of the stock here >>>

SEC Filings (Institutional Ownership Changes) for Moleculin Biotech (NASDAQ:MBRX)

15.52% of Moleculin Biotech stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at MBRX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Moleculin Biotech Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
2/13/2024Armistice Capital LLC3,207,417$2.75M0.0%N/A9.600%Search for SEC Filing on Google Icon
1/17/2024Atticus Wealth Management LLC50,001$43K0.0%N/A0.168%Search for SEC Filing on Google Icon
5/15/2023Sio Capital Management LLC1,010,956$0.97M0.5%-2.5%3.407%Search for SEC Filing on Google Icon
7/25/2022Walker Asset Management LLC20,708$32K0.0%N/A0.072%Search for SEC Filing on Google Icon
4/20/2022Sigma Planning Corp57,500$0.10M0.0%+33.7%0.201%Search for SEC Filing on Google Icon
2/2/2022Sigma Planning Corp43,000$80K0.0%N/A0.150%Search for SEC Filing on Google Icon
11/9/2021BlackRock Inc.270,402$0.81M0.0%-2.5%0.947%Search for SEC Filing on Google Icon
9/17/2021Virtu Financial LLC25,302$93K0.0%N/A0.089%Search for SEC Filing on Google Icon
8/16/2021Occudo Quantitative Strategies LP29,188$0.11M0.0%+31.7%0.102%Search for SEC Filing on Google Icon
8/16/2021State Street Corp59,900$0.22M0.0%N/A0.210%Search for SEC Filing on Google Icon
8/13/2021Geode Capital Management LLC237,586$0.87M0.0%+35.9%0.835%Search for SEC Filing on Google Icon
8/13/2021Vanguard Group Inc.1,047,529$3.84M0.0%+123.6%3.683%Search for SEC Filing on Google Icon
8/12/2021XTX Topco Ltd32,997$0.12M0.0%N/A0.116%Search for SEC Filing on Google Icon
8/5/2021GSA Capital Partners LLP31,120$0.11M0.0%N/A0.109%Search for SEC Filing on Google Icon
5/21/2021Citadel Advisors LLC13,843$56K0.0%N/A0.049%Search for SEC Filing on Google Icon
5/19/2021Squarepoint Ops LLC28,904$0.12M0.0%+134.2%0.102%Search for SEC Filing on Google Icon
5/18/2021Cubist Systematic Strategies LLC26,624$0.11M0.0%N/A0.094%Search for SEC Filing on Google Icon
5/18/2021Citadel Advisors LLC13,843$56K0.0%N/A0.049%Search for SEC Filing on Google Icon
5/14/2021Occudo Quantitative Strategies LP22,158$90K0.0%N/A0.078%Search for SEC Filing on Google Icon
5/12/2021Northern Trust Corp50,731$0.21M0.0%-43.1%0.178%Search for SEC Filing on Google Icon
5/12/2021Geode Capital Management LLC174,822$0.71M0.0%-40.6%0.615%Search for SEC Filing on Google Icon
5/7/2021BlackRock Inc.239,326$0.98M0.0%+449.7%0.841%Search for SEC Filing on Google Icon
4/27/2021Harel Insurance Investments & Financial Services Ltd.10,000$0.14M0.0%N/A0.035%Search for SEC Filing on Google Icon
4/14/2021Taylor Cottrill Erickson & Associates Inc.16,964$69K0.0%-83.3%0.060%Search for SEC Filing on Google Icon
2/10/2021Renaissance Technologies LLC948,503$0.76M0.0%+6.4%7.901%Search for SEC Filing on Google Icon
11/13/2020Truist Financial Corp175,000$0.14M0.0%+25.0%0.284%Search for SEC Filing on Google Icon
8/14/2020Bank of America Corp DE39,900$39K0.0%N/A0.066%Search for SEC Filing on Google Icon
7/31/2020UBS Group AG47,538$46K0.0%+40.2%0.079%Search for SEC Filing on Google Icon
5/15/2020Two Sigma Securities LLC90,062$55K0.0%+556.3%0.169%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Moleculin Biotech logo
Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066 that is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It is also developing WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company was incorporated in 2015 and is headquartered in Houston, Texas.
Read More on Moleculin Biotech

Today's Range

Now: $5.08
Low: $5.02
High: $5.14

50 Day Range

MA: $5.49
Low: $4.28
High: $9.48

52 Week Range

Now: $5.08
Low: $4.28
High: $15.75

Volume

8,388 shs

Average Volume

26,356 shs

Market Capitalization

$11.73 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.85

Who are the company insiders with the largest holdings of Moleculin Biotech?

Moleculin Biotech's top insider investors include:
  1. Walter V Klemp (CEO)
  2. Jonathan P Foster (CFO)
  3. Robert E George (Director)
Learn More about top insider investors at Moleculin Biotech.
The ONE AI Stock to own now. (It’s not Nvidia.)
From Weiss Ratings   |   Ad
Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages of this boom were big … But I believe the real wealth in AI has yet to be made …
Click here to see the presentation now.